Collectively, these findings suggest that ATRA-Corin treatment promotes the displacement of LSD1 and the CoREST repressor complex by the coactivator P300 at RAR-responsive loci, facilitating enhanced H3K27 acetylation and robust transcriptional activation of genes essential for AML cell differentiation. The gene discussed is KDM1A; the disease is acute myeloid leukemia.